Randomized Comparison of 2 Fixation Techniques for Unstable Intertrochanteric Hip Fractures (EMvsIM)

August 14, 2014 updated by: Rudy Reindl

Extramedullary vs. Intramedullary Devices in the Treatment of Unstable Intertrochanteric Hip Fractures

The purpose of this study is to compare the clinical and radiological outcome of patients that are treated with two different orthopedic implants. The study population will consist of patients that have sustained unstable hip fractures. The two different implants will be randomly assigned.

The null hypothesis states that there should not be any significant differences between the two implants.

Study Overview

Status

Completed

Conditions

Detailed Description

Intertrochanteric hip fractures are common injuries in the elderly population. They often signify generalized physical deterioration. Operative management has become the standard of care to prevent life threatening complications and dates back to the 1940's. The design of implants has evolved significantly since then.

The sliding hip screw replaced static fixation of the femoral head in the 1950's. As a result of this improvement in design, failures have been reduced to 9-16%. The sliding hip screw allows for stable collapse of the femoral neck. This can lead to significant shortening of the proximal femur in comminuted fractures.

Current treatment modalities focus on obtaining a satisfactory union of the fracture, often at the expense of anatomical alignment. Severely comminuted fractures treated with a standard plate-hip-screw device thus commonly result in significant degrees of mal-union and shortening. In the past, implants designed to restore and maintain the anatomy of the hip have resulted in high failure rates with the implant breaking out of the femoral head. In the mid 1980's, recognition of this led to the development of various intramedullary devices for fixation of these fractures. The weight-bearing portion of the implant is therefore shifted medially, resulting in reduced lever forces on the implant and femur. Additionally, the IM device does not rely on fixation to the lateral cortex of the femur with screws. From a biomechanical standpoint, the intramedullary device has distinct advantages, as it is a load- sharing device more closely located to the axis of weight bearing than the plate-hip-screw device.

Advances in intramedullary designs have been promising, but the clinical results variable. The relatively high rate of fracture at the tip, specifically at the level of the locking bolts, has hampered the widespread popularity of intramedullary devices. Additionally, the large diameter of the proximal aspect of the implants required extensive reaming of the greater trochanter and partial detachment of the gluteus medius. This may lead to abductor weakness and a Trendelenburg gait. Some studies have found increased re-operation rates for these early hip-nail devices compared to the plate -hip-screw implant. Other studies have shown decreased blood loss and operative time with the nails. A meta-analysis of the literature favors the sliding hip screw design. Unfortunately, most studies focus on radiological failure rate rather than patient function and relate to the first generation of IM devices.

The newest generation of nails (like the IM studied here) has attempted to correct the shortcomings of earlier designs. The proximal aspect of the nail diameter is minimized. The distal locking screw is located far away from the distal end of the nail and the locking bolt is placed in an oblique fashion. Design alterations to the femoral head fixation portion of the nail by using a helical blade rather than a screw may improve fixation in the femoral head. These new designs seem to compare favorably in recent clinical tests. Early mobilization for patients with the intramedullary device (IM) seems to be better.

Results of the pilot study indicate an earlier return to full mobility and shorter operating time in the IM group. This study included all intertrochanteric fracture types and did not demonstrate a clear benefit of the IM in many other parameters. The currently proposed multi-centre study will focus on the unstable A2 intertrochanteric fracture pattern.

Considering the significantly increased cost of the new intramedullary devices compared to the standard plate-hip-screw, a significant overall improvement in patient function should be realized before the general use of these new devices could be recommended.

Study Type

Interventional

Enrollment (Actual)

200

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. 55 years or older
  2. Type A2 Intertrochanteric fractures
  3. Mono trauma
  4. Medically fit for surgery
  5. Less than 2 weeks post fracture

Exclusion Criteria:

  1. Fractures due to malignancy
  2. Non-ambulatory pre-fracture
  3. Severe dementia
  4. Limited life expectancy due to significant medical co-morbidities
  5. Medical contraindication to surgery
  6. Inability to comply with rehabilitation of form completion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: EM device
Extramedullary Device (EM)
Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
Other Names:
  • Extramedullary plate/ screw device , Intramedullary nail
Active Comparator: IM device
Intramedullary Device (IM)
Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
Other Names:
  • Extramedullary plate/ screw device , Intramedullary nail

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Timed 2 minute walking distance
Time Frame: 6 weeks, 3 months, 6 months and 12 months
6 weeks, 3 months, 6 months and 12 months
TUG (Time up and go) test
Time Frame: 6 weeks, 3 months, 6 months and 12 months
6 weeks, 3 months, 6 months and 12 months
Trendelenburg's test: pelvic drop
Time Frame: 6 weeks, 3 months, 6 months and 12 months
6 weeks, 3 months, 6 months and 12 months
Fracture classification: Mueller/ AO, displacement, time to union, heterotopic ossification and shortening.
Time Frame: 6 weeks, 3 months, 6 months and 12 months
6 weeks, 3 months, 6 months and 12 months
FIM (Functional Independence Measure)
Time Frame: 6weks, 3months, 6months and 12months
6weks, 3months, 6months and 12months
LEM (Lower Extremity Measure)
Time Frame: 6weeks, 3months, 6months and 12 months
6weeks, 3months, 6months and 12 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Secondary Outcome Variable: Transfusions
Time Frame: 6 weeks, 3 months, 6 months and 12 months
6 weeks, 3 months, 6 months and 12 months
Pre and Post operative Hgb
Time Frame: 6 weeks, 3 months, 6 months and 12 months
6 weeks, 3 months, 6 months and 12 months
Complications/ Re-operation
Time Frame: 6 weeks, 3 months, 6 months and 12 months
6 weeks, 3 months, 6 months and 12 months
Length of surgery and hospital stay
Time Frame: 6 weeks, 3 months, 6 months and 12 months
6 weeks, 3 months, 6 months and 12 months
Weight bearing status post-op
Time Frame: 6 weeks, 3 months, 6 months and 12 months
6 weeks, 3 months, 6 months and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Rudy Reindl, MD FRCSC, McGill University Health Centre/Research Institute of the McGill University Health Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2007

Primary Completion (Actual)

November 1, 2012

Study Completion (Actual)

November 1, 2012

Study Registration Dates

First Submitted

January 9, 2008

First Submitted That Met QC Criteria

January 17, 2008

First Posted (Estimate)

January 18, 2008

Study Record Updates

Last Update Posted (Estimate)

August 18, 2014

Last Update Submitted That Met QC Criteria

August 14, 2014

Last Verified

August 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • GEN #07-065

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hip Fractures

Clinical Trials on Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)

3
Subscribe